Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Clostridium difficile colitis? 39 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Clostridium difficile colitis have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.1% of all adverse event reports for OCRELIZUMAB.

39
Reports of Clostridium difficile colitis with OCRELIZUMAB
0.1%
of all OCRELIZUMAB reports
4
Deaths
24
Hospitalizations

How Dangerous Is Clostridium difficile colitis From OCRELIZUMAB?

Of the 39 reports, 4 (10.3%) resulted in death, 24 (61.5%) required hospitalization, and 2 (5.1%) were considered life-threatening.

Is Clostridium difficile colitis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 39 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Clostridium difficile colitis?

CYCLOPHOSPHAMIDE (717) PREDNISONE (619) DEXAMETHASONE (575) METHOTREXATE (562) ETOPOSIDE (503) CYTARABINE (489) VINCRISTINE (482) LENALIDOMIDE (388) METHYLPREDNISOLONE (385) CIPROFLOXACIN (378)

Which OCRELIZUMAB Alternatives Have Lower Clostridium difficile colitis Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Clostridium difficile colitis Reports All Drugs Causing Clostridium difficile colitis OCRELIZUMAB Demographics